Pyxis Oncology (PYXS) news

Pyxis Oncology announces closing of up to $282.6 million public offering

Pyxis Oncology, Inc. (Nasdaq: PYXS) has announced the closing of its public offering, which raised up to $282.6 million in gross proceeds. The offering included 36,047,919 shares of common stock and 1,883,121 pre-funded warrants, along with accompanying common warrants to purchase 49,310,352 shares…

Pyxis Oncology prices offering at combined $2.90/shr, warrant

Pyxis Oncology announces pricing of up to $282.6 million public offering

Pyxis Oncology announces proposed public offering

Pyxis Oncology, Inc. (NASDAQ: PYXS) has announced a private placement of equity securities, which may serve as a precursor to a broader public offering. On June 30, 2026, the company entered into a securities purchase agreement with institutional and accredited investors, under which it agreed to…

Pyxis Oncology: Terminates $150.00M ATM offering, no shares sold to date - SEC filing

Pyxis Oncology, Inc. (NASDAQ: PYXS) has terminated its $150 million at-the-market (ATM) stock offering program, according to an SEC filing. The company had initially established the ATM program as a flexible capital-raising mechanism but has now opted to discontinue it, with no shares having been…